Document Detail

Predictive value of HIV-1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment-experienced patients.
MedLine Citation:
PMID:  22276745     Owner:  NLM     Status:  Publisher    
OBJECTIVES: The aim of the study was to determine the prognostic value of HIV replication capacity (RC) for subsequent antiretroviral (ARV) treatment response in ARV-experienced patients. METHODS: RC and phenotypic resistance testing were performed at baseline and week 12 on plasma samples from patients randomized to undergo a 12-week ARV drug-free period (ARDFP) or initiate immediate salvage therapy (no-ARDFP group) in the Options in Management with Antiretrovirals (OPTIMA) trial. Dichotomous and incremental phenotypic susceptibility scores (dPSSs and iPSSs, respectively) were calculated. The predictive value of RC and PSS for ARV therapy response and/or ARDFP was evaluated using multivariate regression analysis and Pearson correlations. RESULTS: In 146 no-ARDFP subjects, baseline RC (50.8%) did not change at week 12 and was not correlated with CD4 cell count or viral load changes at week 12 (P = 0.33 and P = 0.79, respectively) or at week 24 (P = 0.96 and P = 0.14, respectively). dPSS predicted virological but not CD4 cell count response to ARV therapy at weeks 12, 24 and 48 (P = 0.002, P < 0.001 and P = 0.005, respectively). RC was significantly correlated with dPSS and iPSS at baseline, but did not increase their predictive value. In the 137 ARDFP patients, RC increased significantly (from 52.4 to 85.8%), but did not predict CD4 cell count and viral load changes during ARDFP (P = 0.92 and P = 0.26, respectively). RC after ARDFP did not predict subsequent CD4 cell count and viral load changes 12 weeks following ARV treatment reinitiation (P = 0.90 and P = 0.29, respectively). CONCLUSIONS: We found no additional predictive value of replication capacity for virological or immunological responses (above what PSS provides) in patients undergoing salvage ARV treatment.
R Bedimo; T Kyriakides; S Brown; J Weidler; Y Lie; E Coakley; M Holodniy
Related Documents :
17006875 - A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (aricep...
17305255 - What happens to people after malignant cord compression? survival, function, quality of...
16639475 - Trends in five-year survival of patients discharged after acute myocardial infarction.
22767995 - Assessment of malignancy risk in patients with multiple sclerosis treated with intramus...
4002785 - Short-term, high-dose muzolimine treatment in patients with chronic renal failure and a...
24781615 - Calcaneoplasty and reattachment of the achilles tendon for insertional tendinopathy.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-26
Journal Detail:
Title:  HIV medicine     Volume:  -     ISSN:  1468-1293     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897392     Medline TA:  HIV Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 British HIV Association.
Veterans Affairs North Texas Health Care System, Dallas, TX, USA; University of Texas Southwestern, Dallas, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adsorption and disruption of lipid bilayers by nanoscale protein aggregates.
Next Document:  Factors influencing integration of TB services in general hospitals in two regions of China: a quali...